Literature DB >> 19920216

Neonatal growth and regeneration of beta-cells are regulated by the Wnt/beta-catenin signaling in normal and diabetic rats.

Florence Figeac1, Benjamin Uzan, Monique Faro, Noura Chelali, Bernard Portha, Jamileh Movassat.   

Abstract

Wnt/beta-catenin signaling is critical for a variety of fundamental cellular processes. Here, we investigated the implication of the Wnt/beta-catenin signaling in the in vivo regulation of beta-cell growth and regeneration in normal and diabetic rats. To this aim, TCF7L2, the distal effector of the canonical Wnt pathway, was knocked down in groups of normal and diabetic rats by the use of specific antisense morpholino-oligonucleotides. In other groups of diabetic rats, the Wnt/beta-catenin pathway was activated by the inhibition of its negative regulator GSK-3beta. GSK-3beta was inactivated by either LiCl or anti-GSK-3beta oligonucleotides. The beta-cell mass was evaluated by morphometry. beta-cell proliferation was assessed in vivo and in vitro by BrdU incorporation method. In vivo beta-cell neogenesis was estimated by the evaluation of PDX1-positive ductal cells and GLUT2-positive ductal cells and the number of beta cells budding from the ducts. We showed that the in vivo disruption of the canonical Wnt pathway resulted in the alteration of normal and compensatory growth of beta-cells mainly through the inhibition of beta-cell proliferation. Conversely, activation of the Wnt pathway through the inhibition of GSK-3beta had a significant stimulatory effect on beta-cell regeneration in diabetic rats. In vitro, GSK-3beta inactivation resulted in the stimulation of beta-cell proliferation. This was mediated by the stabilization of beta-catenin and the induction of cyclin D. Taken together, our results demonstrate the involvement of the canonical Wnt signaling in the neonatal regulation of normal and regenerative growth of pancreatic beta-cells. Moreover, we provide evidence that activation of this pathway by pharmacological maneuvers can efficiently improve beta-cell regeneration in diabetic rats. These findings might have potential clinical applications in the regenerative therapy of diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19920216     DOI: 10.1152/ajpendo.00538.2009

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  28 in total

1.  Proteomic characterisation reveals active Wnt-signalling by human multipotent stromal cells as a key regulator of beta cell survival and proliferation.

Authors:  Miljan Kuljanin; Gillian I Bell; Stephen E Sherman; Gilles A Lajoie; David A Hess
Journal:  Diabetologia       Date:  2017-07-14       Impact factor: 10.122

Review 2.  Human β-cell regeneration: progress, hurdles, and controversy.

Authors:  Agata Jurczyk; Rita Bortell; Laura C Alonso
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-04       Impact factor: 3.243

Review 3.  Role of Wnt signaling pathways in type 2 diabetes mellitus.

Authors:  Jing Chen; Chong Ning; Jingjing Mu; Dongnan Li; Yan Ma; Xianjun Meng
Journal:  Mol Cell Biochem       Date:  2021-02-10       Impact factor: 3.396

4.  Local in vivo GSK3β knockdown promotes pancreatic β cell and acinar cell regeneration in 90% pancreatectomized rat.

Authors:  Florence Figeac; Anissa Ilias; Danielle Bailbe; Bernard Portha; Jamileh Movassat
Journal:  Mol Ther       Date:  2012-07-24       Impact factor: 11.454

5.  Downregulation of Sfrp5 promotes beta cell proliferation during obesity in the rat.

Authors:  Sandra A Rebuffat; Joana M Oliveira; Jordi Altirriba; Nuria Palau; Ainhoa Garcia; Yaiza Esteban; Belen Nadal; Ramon Gomis
Journal:  Diabetologia       Date:  2013-09-05       Impact factor: 10.122

6.  Proproliferative and antiapoptotic action of exogenously introduced YAP in pancreatic β cells.

Authors:  Ting Yuan; Sahar Rafizadeh; Zahra Azizi; Blaz Lupse; Kanaka Durga Devi Gorrepati; Sushil Awal; Jose Oberholzer; Kathrin Maedler; Amin Ardestani
Journal:  JCI Insight       Date:  2016-11-03

7.  In vitro scan for enhancers at the TCF7L2 locus.

Authors:  D Savic; S Y Park; K A Bailey; G I Bell; M A Nobrega
Journal:  Diabetologia       Date:  2012-09-26       Impact factor: 10.122

8.  A euglycaemic/non-diabetic perinatal environment does not alleviate early beta cell maldevelopment and type 2 diabetes risk in the GK/Par rat model.

Authors:  A Chavey; D Bailbé; L Maulny; J P Renard; J Movassat; B Portha
Journal:  Diabetologia       Date:  2012-10-12       Impact factor: 10.122

9.  Gene regulatory network reveals oxidative stress as the underlying molecular mechanism of type 2 diabetes and hypertension.

Authors:  Jesmin Jesmin; Mahbubur Sm Rashid; Hasan Jamil; Raquel Hontecillas; Josep Bassaganya-Riera
Journal:  BMC Med Genomics       Date:  2010-10-13       Impact factor: 3.063

10.  TCF7L2 rs7903146 impairs islet function and morphology in non-diabetic individuals.

Authors:  O Le Bacquer; J Kerr-Conte; S Gargani; N Delalleau; M Huyvaert; V Gmyr; P Froguel; B Neve; F Pattou
Journal:  Diabetologia       Date:  2012-08-22       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.